GlassScriptPhysician profile
Bernard A Gasch
NPI 1407851363
$4,710.35
in general payments reported to CMS, 2019-2025
31 companies · $781 in 2025
The $781 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $326 · 2021: $562 · 2022: $636 · 2023: $253 · 2024: $792 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.63 |
| Education | $342.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,084.22 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $753.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $388.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $318.68 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $268.24 | 2022-2024 | Sotyktu |
| Pfizer INC. | $261.31 | 2019-2024 | |
| Ucb, INC. | $214.22 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $184.14 | 2019-2025 | |
| Lilly USA, LLC | $135.44 | 2019-2025 | Ebglyss |
| Genzyme Corporation | $131.81 | 2019-2022 | |
| Galderma Laboratories, L.P. | $115.42 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $111.03 | 2022 | |
| Biofrontera INC. | $92.62 | 2019-2021 | |
| Merz North America, INC. | $88.66 | 2021-2024 | |
| Dermira, INC. | $68.71 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.82 | 2019-2020 | |
| Leo Pharma INC. | $60.94 | 2022-2025 | Anzupgo |
| Merck Sharp & Dohme LLC | $47.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.23 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Mayne Pharma Commercial LLC | $39.87 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $36.24 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $30.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.98 | 2022 | |
| Sandoz INC. | $24.10 | 2019 | |
| Vyne Pharmaceuticals INC. | $22.62 | 2020 | |
| Almirall LLC | $22.59 | 2019 | |
| Incyte Corporation | $22.53 | 2021 | |
| Medtronic, INC. | $20.14 | 2022 | |
| Strata Skin Sciences, INC. | $18.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Gasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.